PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

 PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

Shots:

  • BioVectra to provide its integrated CDMO services for the manufacturing of API of bentracimab for use in PhaseBio’s ongoing global studies and global commercial use upon regulatory approval
  • PhaseBio plans to integrate API manufactured at a commercial scale at BioVectra into the ongoing P-IIb and P-III REVERSE-IT study to support the global regulatory filings
  • The agreement will enable PhaseBio to supply bentracimab at launch in the US. Bentracimab is a monoclonal antibody fragment that demonstrated immediate and sustained reversal of the antiplatelet activity of Brilinta (ticagrelor)

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post